R is for “Results”.
My PULSE assignment has coincided with the mid term Review of the GSK-Save Partnership. This means that we are Reviewing the Results of all the programmes and initiatives to date, i.e. what the Partnership has Realised in the first 2.5 years. In my monitoring and evaluation Role, I have been working with the individual workstreams to collate the data, which are then checked with Rigour to ensure they meet the Required level of Robustness. This has Resulted in a colossal spreadsheet containing thousands of datapoints. This is evaluated then further summarised to Reduce it down to a manageable sized piece of information that can be Reported to provide an accurate Reflection of achievements to date.
Speaking of achievements, there has been some good news from the Research and Development (R&D) workstream since my last blog and one which Relates back to my “home” department in GSK. A Regulatory application has been submitted to the European Medicines Agency (EMA) for the antiseptic chlorhexidine gel. (I cross-Refer you back to “C week” for more information about its use with newborns). The submission Represents a major milestone Reached by the Partnership which combines expertise and Resources to help save the lives of children in developing countries. The EMA intends to provide a scientific opinion on the submission in a Reduced time frame and, if approved for use, GSK will offer it at a not-for-profit price and will share its manufacturing knowledge with others to enable it to be made locally.
One further workstream that I’d like to introduce you to is known as 20% Reinvestment/healthcare workers workstream. 6 years ago, GSK took the decision to Reinvest 20% of the profits it generates in the very poorest nations, back into strengthening healthcare systems in those countries. By working with 3 NGOs and Recycling one-fifth of profits in the least developed countries, it is possible to provide training to healthcare workers alongside Raising awareness of the importance of local healthcare provision within communities and at government level. Save the Children is partnering with GSK to deliver these activities predominantly in West African countries. It is believed that this is a good Return on investment – for example training local healthcare providers can Raise vaccination Rates and Reduce maternal and newborn deaths; making a Real difference to people’s lives.